Recce Pharmaceuticals Ltd
RECEF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$63.62M
Close$
$-0.02
108.5% downside
Current Fair Value
108.5% downsideOvervalued by 108.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $63.62 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.05 |
| Beta | 0.39 |
| Outstanding Shares | 289,183,422 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -6.95 |
|---|---|
| PEG | 6.22 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
March 1, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Recce Pharmaceuticals Ltd
8 employees
CEO: James Hamilton-Bray Graham
Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The...